Rapid response of nail psoriasis to etanercept

Journal of Rheumatology

Volumn 35, Issue 3, 2008, Pages 544-545

  Rallis, Efstathios ^c   Stavropoulou, Evgenia ^a   Rigopoulos, Dimitris ^b   Verros, Constantinos ^c  

^a 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETANERCEPT; ETRETIN;

ADULT; CASE REPORT; HUMAN; HYPERKERATOSIS; LETTER; MALE; NAIL PSORIASIS; ONYCHOLYSIS; PRIORITY JOURNAL; PSORIASIS;

ADULT; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; NAIL DISEASES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 40649085123     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Cassell S, Kavanaugh A. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:1452-6.
2. de Rie M, Giannetti S, Walker J, et al. Nail psoriasis improves after 12 weeks of etanercept therapy in patients with moderate to severe psoriasis. Proceedings, 16th Congress of the European Academy of Dermatology and Venereology, Vienna, Austria, May 16-20 2007; Poster 1117:193.
3. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26.
4. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007;20:60-7.
5. Jiaravuthisan M, Sasseville D, Vender RB, et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27.